A 64-year-old woman with recurrent mitral valve stenosis was hospitalized 30 years after open commissurotomy. Severe right cerebral embolism occurred at age 58, with left hemiparesis. She was debilitated with cardiac cachexia. Based on symptomatic valvular disease findings, surgery was considered, but deemed too high risk due to the combined insufficiencies. She refused this surgical operation and requested conservative therapy. Optimized medication and cardiac rehabilitation improved her general condition allowing transfer to another hospital. We explained the short life expectancy both to her and to her family. They decided to transfer to a hospice at a chronic care hospital and she was given best supportive care. Eventually, her urine output decreased and respiration deteriorated. She and her family refused resuscitation in the event of cardiopulmonary arrest, requesting only suffering reduction. Thus, continuous intravenous infusion of morphine was started. The optimized doses for pain alleviation were determined in consultation with palliative care specialists and maximized her consciousness level for the last four days.
Introduction
Patients with chronic heart failure (CHF) are increasing in developed countries with aging populations [1] . Although advances in treatment have prolonged survival, CHF becomes terminal after repeated remissions and exacerbations. Patients and caregivers face challenging issues including quality of life and end-of-life CHF management. Standardizing CHF treatment is difficult due to background diversity. Moreover, because determining whether CHF is end-stage is difficult for healthcare providers, clinical decisions about therapeutic aggressiveness are challenging. Thus, life-prolonging invasive intervention is often continued, despite end-stage CHF. One-year survival is reportedly ≤50% in New York Heart Association (NYHA) class III/IV patients, a prognosis similar to that of stage IIIA lung cancer patients [2, 3] . However, CHF patients and families often do not recognize this poor prognosis. Patients with little long-term survival potential should receive symptom-palliating treatment first, with hospice care with opioids for dyspnea among the options [4] . Patients and families need prognostic information and treatment options for end-stage CHF, with treatment decisions being made cooperatively. Estimated 70,000-100,000 CHF patients live in Hiroshima prefecture. The Heart Failure Center of Hiroshima University Hospital plays a central role in promoting a regional heart failure-following network system by multiple medical facilities. Herein, we report a patient with end-stage CHF, receiving optimized care at our hospital and transferred to hospice at a regional medical facility with consent.
Case report
A 64-year-old woman underwent open commissurotomy for mitral valve stenosis at age 34 years. Severe right cerebral embolism occurred at age 58, with left hemiparesis caused by large cerebral infarction (Fig. 1 ). Echocardiography revealed recurrent mitral valve stenosis, moderate aortic valve stenosis, severe secondary tricuspid valve regurgitation, and significant right heart dilatation. She refused reoperation, despite being a surgical candidate, and continued medical treatment at a nearby clinic.
Anorexia, emaciation (height 150 cm, weight 33 kg), and hepatomegaly developed in November 2011. By December, she was debilitated with cardiac cachexia and orthopnea. Compromised activity prompted admission to our hospital in February 2012 (Table 1) . She had NYHA class III heart failure with impaired activities of daily living/quality of life status ( Table 2) , cardiomegaly (cardiothoracic ratio, 0.79), and increased pulmonary vessel shadows. Echocardiography revealed decreased left ventricular wall motion (left ventricular ejection fraction, 46%), severe aortic valve stenosis (aortic valve area, 0.9 cm 2 ; maximum velocity, 4 m/s), and severe mitral valve stenosis (mitral valve area, 1.0 cm 2 ) with secondary right heart failure (tricuspid pressure gradient, 41 mmHg) ( Figs. 2 and 3 ). Based on symptomatic valvular disease findings at her age, surgery was considered, but deemed too high risk due to the combined valvular diseases. She and her family requested conservative treatment. Doses of diuretic agents were optimized, increasing urine output and ameliorating dyspnea. Cardiac rehabilitation with indoor walking was started despite paresis and rehabilitation for cerebral infarction was also performed to prevent contractures and improve dysarthria ( Table 3) .
In April 2012, her general condition improved, allowing transfer to another hospital. We explained the poor prognosis and short life expectancy to the patient and her family. They requested continuation of conservative therapy. The patient was thus referred for follow-up to a facility near her home. Transfer was scheduled to another chronic care facility following admission to a nearby general hospital. At the general hospital, she was favorably treated for CHF and lumbago in May 2012. Urine output and edema were controlled with thiazide diuretics (Fig. 4 ). She was transferred to hospice at a chronic care hospital near her home in mid-June 2012. She was given a mildly salt-restricted, adjusted for edema, high-calorie and high-protein diet. She received appropriate supplements when anorexia worsened. In early July 2012, her respiratory state deteriorated after preceding oliguria. She and her family again refused resuscitation in the event of cardiopulmonary arrest, requesting only suffering reduction. Thus, palliative care with opioids was started: continuous intravenous infusion of morphine via a syringe pump was started. The optimized doses for pain alleviation were determined in consultation with a palliative care specialist ( Fig. 5 ). Pain management maximized her consciousness level for four days before death, without inducing respiratory depression. We later received a letter of thanks from her family.
Discussion
We often found it difficult to explain the prognosis to endstage heart failure patients and their families. Repeated remissions and exacerbations, with patients occasionally overcoming acute exacerbations, can make them optimistic [5] . Thus, healthcare providers must explain the prognosis with appropriate timing and support end-of-life preferences of patients and families. In Japan, CHF patients are usually hospitalized in general wards, and aggressive procedures are continued until ineffectual. Patients and family members therefore finally face inevitable end-of-life situations, and are often not prepared for death. Most in-patients with severe CHF have not consulted physicians about cardiopulmonary resuscitation and there are differences of opinion between patients and physicians [6] . Prognosis is a sensitive topic for patients and Fig. 3 . Electrocardiogram revealed sinus tachycardia and right axis deviation. II, III, aVF, V1, and V2 leads showed strain type T wave inversion. families. Therefore, physicians should fully explain therapeutic strategies for end-stage CHF while the condition remains stable, allowing patients and families to specify types of care desired and comfort measures. Practically, it is not exceptional to provide palliative care for patients with end-stage heart failure. This process would ultimately help satisfy end-of-life patients and families as well.
Another medical issue is the change in the medical care system in Japan. More specifically, medical care should have continuity, i.e. acute/sub-acute stage beds, and chronic care beds in hospitals, followed by nursing homes, residential services, and at-home services. Moreover, hospitals should strengthen their capacity to receive patient referrals who have substantial needs for medical treatment from acute stage. In particular, end-of-life patients and their families can place great confidence in continuity of tangible information about medical care. Thus, consistency of explanations and treatment approaches is ensured, being potentially reassuring to end-of-life patients and their families. It is important to provide continuity of tangible information to patients. Thus, we healthcare providers record explanations in a notebook for heart failure patients published by the Regional Health Care Council of Hiroshima Prefecture. Patients are advised to carry it to promote early initiation of rehabilitation therapy, community cooperation, and support at discharge. In caring for end-stage CHF, serious consideration must be given to treatment choices focusing not only on improving outcomes but also quality of life and provision of tailor-made explanations to obtain informed consent, as in advanced cancer cases. To improve palliative care for CHF with repeated abrupt exacerbations and remissions, as compared with other diseases during the end-of-life period, it is essential to communicate between various healthcare providers and patients and to maintain good partnerships with families until death.
Various symptoms can be problematic for end-stage CHF patients, with respiratory distress being common and causing significant suffering [7, 8] . Intense pain, dyspnea, and distress may occur for three days before death [9] . In our patient, opioids relieved symptoms for her final four days. Analgesia with opioids and sedation with diazepam and midazolam are reportedly useful for eliminating the discomfort [10] . Diuretics, used for the treatment of heart failure, are effective in relieving respiratory distress due to over-hydration. Ventilation-perfusion mismatch and atrophy of respiratory muscles are involved in respiratory distress, although the mechanisms are not understood [11] . Diuretics and non-pharmacological therapies including salt and/or water restriction are effective for respiratory distress. However, respiratory distress is difficult to control in end-stage CHF patients even with these treatments.
Opioids relieve respiratory symptoms of cancer patients. In the USA and Europe, opioids are advocated for pain control in end-oflife CHF care [12] . In Japan, where terminal care for patients with end-stage CHF is being recognized by the general public, pain relief and sedation are controversial [13] . There are no large clinical studies on opioids for CHF, but a few randomized controlled studies demonstrated opioid efficacy [14] . Indeed, two-thirds of patients with advanced heart failure have been reported to have severe pain [15] . So we need to initiate opioid use, when end-stage patients feel refractory pain or dyspnea.
The mechanism of action involves vasodilatation and effects on lung and brain respiratory receptors. Adverse effects of opioids include bradycardia, hypotension, and respiratory depression. Dosage adjustment is absolutely required. Even low-dose opioids reportedly relieve respiratory distress, making them an important option for treating intractable respiratory distress in patients with end-stage CHF [16] .
Hospice care is becoming increasingly important, but noncancer patients rarely receive it in Japan. However, hospice can be an option for end-stage CHF patients to spend their final days with relief of pain, symptoms, and mental distress [17] . Transfer to hospice is preferred for patients with severe psychological symptoms or needing expert healthcare and opioids. We need to ensure that we can provide palliative care in hospice, whoever needs it in the near future. Another study [18] demonstrated the number of patients dying at a hospice and the percentage who obtained palliative care to be lower in CHF than in cancer patients. Regarding end-of-life care outside medical facilities, patients may die at home if they can receive palliative care supervised by a qualified expert. However, CHF patients have complex problems different from those of other diseases [19] . Our patient was able to spend her last 72 h free of distress with opioid administration at a stable dose. Our experience with this case confirms previous results demonstrating that opioids can be used safely and effectively for relieving symptoms during end-of-life heart failure [20] .
Conclusion
Heart-failure hospice is potentially a place to die for end-of-life CHF patients, attended by their families and healthcare providers.
